Monovalent anti-cd3 adjuvants

Abstract

This document provides methods and materials related to using monovalent anti-CD3 antibodies (e.g., monovalent anti-CD3 Fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-CD3γε Fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-CD3γε Fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of T cell immune function, as well as methods and materials for using monovalent anti-CD3γε Fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided.

What is claimed is: 
     
         1 . A method for increasing an immune response against an antigen, wherein said method comprises administering a composition comprising a monovalent anti-CD3γε antibody preparation and said antigen or nucleic acid that expresses said antigen to a mammal, wherein said monovalent anti-CD3γε antibody preparation comprises Fab fragments of an anti-CD3γε antibody, and wherein said mammal produces an immune response against said antigen that is increased as compared to an immune response produced against said antigen when said antigen or said nucleic acid is administered to a comparable mammal in the absence of said monovalent anti-CD3γε antibody preparation. 
     
     
         2 . The method of  claim 1 , wherein said mammal is a human, and said Fab fragments are Fab fragments of an anti-human CD3γε antibody. 
     
     
         3 . The method of  claim 1 , wherein said Fab fragments are Fab fragments of a humanized anti-human CD3γε antibody. 
     
     
         4 . The method of  claim 1 , wherein said Fab fragments are Fab fragments of a fully human anti-human CD3γε antibody. 
     
     
         5 . The method of  claim 1 , wherein said antigen is a tumor associated antigen. 
     
     
         6 . The method of  claim 5 , wherein said tumor associated antigen is a polypeptide. 
     
     
         7 . The method of  claim 1 , wherein said antigen is within an extract from a whole tumor cell lysate. 
     
     
         8 . The method of  claim 1 , wherein said method comprises administering said antigen to said mammal. 
     
     
         9 . The method of  claim 1 , wherein said method comprises administering said nucleic acid to said mammal.